ONCAlert | 2017 San Antonio Breast Cancer Symposium

Combination of Veliparib and Chemotherapy in BRCA-Positive Breast Cancer

Hyo Sook Han, MD
Published Online: 8:59 AM, Sat December 10, 2016


Hyo Sook Han, MD, medical oncologist, Moffitt Cancer Center, discusses results of the phase II BROCADE trial, which evaluated the combination of the PARP inhibitor veliparib with carboplatin/paclitaxel in patients with BRCA-positive breast cancer.

Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.